However, there is an absence of large clinical trials specifically designed to document the safety when increases in somatostatin analog dosing are needed in patients who do not achieve their treatment goals.
To fully explore and communicate any potential risks, we conducted a literature review and present a summary of the studies documenting the safety and tolerability of dose optimization with somatostatin analogs in patients with acromegaly and NET. 
MATERIALS AND METHODS
A literature search of PubMed from January 1965
to September 2010 was performed using the search terms "acromegaly" or "neuroendocrine tumor" and "dose optimization" or "dose 
RESULTS

Acromegaly
The of treatment are to attain biochemical control, control tumor growth, and prevent recurrence. 15, 22 For most patients, transsphenoidal adenomectomy (TSA) by a dedicated and experienced pituitary neurosurgeon is the first-line treatment option. [23] [24] [25] [26] In addition to surgical treatment, the American Association of Clinical Endocrinologists (AACE) reviews the pharmacological options for the treatment of acromegaly and recommends medical therapy for the treatment of persistent acromegaly and for treatment of patients who are not candidates for surgery. 3, 21 The options for medical therapy include: somatostatin analogs, dopaminereceptor agonists, and GH-receptor analogs.
Somatostatin analogs are the first choice 21 and should be considered before undergoing surgery to improve severe co-morbidities that prevent or could complicate immediate surgery, 27 as a first-line therapy when there is a low probability of surgical cure, 28, 29 after surgery has failed to achieve biochemical control, or in combination with radiation therapy. 
Somatostatin Analog Therapy in Patients with Acromegaly
Somatostatin analogs have a well-established efficacy profile and patients do not typically discontinue treatment due to adverse events.
A recent meta-analysis reviewed the efficacy results of more than 600 patients (regardless of somatostatin analog responsiveness). 30 The analysis determined that treatment with long-acting somatostatin analogs as secondary therapy improved biochemical control.
Specifically, the reported proportion of patients in whom there was a reduction in GH level (<2.5 μg/L) and normalization of IGF-1 was 57% and 67%, respectively, following octreotide LAR therapy, and 48% and 47%, respectively, following therapy with lanreotide depot. in 43% of patients and GH levels ≤1 μg/L were achieved in 45% of the patients enrolled in the study. 43 The majority of adverse events in this study were mild or moderate in severity, with 57% of patients reporting at least one episode of diarrhea and 27% of patients reporting abdominal pain. 43 LAR to achieve control of GH (<2 μg/L) and normalization of IGF-1. 44 Overall, high-dose treatment with octreotide LAR controlled Previously, NET were divided into three subtypes (foregut, midgut, and hindgut) based on their embryologic origin (Table 2A) ; 48, 49 however, recently the practice has changed to classify the tumors based on the location of primary origin, differentiation/tumor-node-metastasis (TNM)
grade, and stage (Table 2B) . 50, 51 In addition,
NET are usually characterized as clinically symptomatic (functioning) or silent (nonfunctioning) tumors, depending on whether the peptides that are secreted produce symptoms.
Functioning NET are further classified by the peptides that are secreted into the system Most importantly, adverse events were balanced between the two groups. 61 Finally, a retrospective analysis studied the efficacy and tolerability of 
